Navigation Links
Renovis Reports Fourth Quarter and Full Year 2007 Financial Results
Date:3/14/2008

inical trials in 2008. Additionally, Renovis' two other preclinical programs continued to move forward toward IND-enabling studies. Equally important was our announcement in the third quarter that we had agreed to merge the company with Evotec, a Hamburg, Germany-based biotechnology company focused on the discovery and development of potential treatments for diseases of the central nervous system (CNS). The combination of the two companies, which is expected to be completed in the first half of 2008, secures a place for Renovis' preclinicial candidates in a robust CNS and inflammation-oriented pipeline, and creates a critical mass of scientific expertise and infrastructure. We believe that the prospect of an even stronger financial base as well as a globally integrated discovery and development team will provide enhanced value for our shareholders."

Option Grants Under NASDAQ Marketplace Rule 4350

In accordance with NASDAQ Marketplace Rule 4350, Renovis granted employment inducement stock options to one non-executive employee hired between November 7, 2007 and March 14, 2008 to support the Company's research and development efforts.

The inducement stock options cover an aggregate of 3,200 shares of common stock and are classified as non-qualified stock options with an exercise price equal to the fair market value on the date of grant. These options were granted without stockholder approval pursuant to NASDAQ Marketplace Rule 4350 (i)(1)(A)(iv) with the Company's standard stock option terms, including a 10- year term and vesting over fours years.

About Renovis

Renovis is a biopharmaceutical company focused on the discovery and development of drugs for major medical needs in the areas of neurological and inflammatory diseases. The Company's proprietary research programs focus on the purinergic receptors, P2X3 and P2X7, for the potential treatment of pain and inflammatory diseases. In addition, Renovis has a worldwide collaboration an
'/>"/>

SOURCE Renovis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Renovis to Present at CIBC World Markets Healthcare Conference
2. Renovis Reports Third Quarter 2007 Financial Results
3. Evotec Provides Update on Planned NASDAQ Listing in the Context of its Announced Acquisition of Renovis
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. QMed, Inc. Reports July Medicare SNP Enrollments
6. Phlo Affiliate Reports Expanded Coverage to Oregon Border
7. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
8. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
9. Carrington Reports Second Quarter 2007 Results
10. Avitar Reports Third Quarter Financial Results for Fiscal 2007
11. Response Genetics Reports Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... (PRWEB) December 23, 2014 Earlier this year ... Sherley, director of the Adult Stem Cell Technology Center, LLC ... under appreciated unique property of adult tissue stem cells. ... the Past, Important for the Future,” embodied the essence of ...
(Date:12/24/2014)... MD (PRWEB) December 23, 2014 On ... H.R. 83, the Omnibus and Continuing Resolution Appropriations Act ... a condition eligible to receive funding through the Congressionally ... of Defense (DoD). The Hydrocephalus Association (HA), working in ...
(Date:12/24/2014)... 23, 2014 The report provides ... definition, classification, application and industry overview. This report ... cost structure. Production is separated by regions, technology ... materials, equipment, downstream client survey, marketing channels, industry ...
(Date:12/24/2014)... The report expects global cell isolation and expansion market ... carefully analyzed data about the vital drivers, restraints, trends, opportunities, ... Report @ http://bit.ly/1yUxy0T , According to the report, ... at an impressive CAGR during near future. It expects this ...
Breaking Biology Technology:Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 2Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 3Adult Stem Cell Technology Center, LLC’s Director Sherley's Address on What’s Holding Back Regenerative Medicine Featured on Omics Group Website 4Rare Brain Condition Now Eligible for Department of Defense Research Dollars 2Worldwide Methyl Mercaptan Market 2015-2020 Forecasts on Development & Trends Now Available at ReportsnReports.com 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 2The Cell Expansion Market is Expected to Reach $14.8 billion by 2019 - New Research Report by MarketsandMarkets 3
... Nov. 24 Boston Scientific,Corporation (NYSE: BSX ) ... which is being held December 2 - 3 in New ... will make a 30-minute presentation on,Tuesday, December 2, beginning at ... A live webcast of Mr. Tobin,s remarks will be ...
... CLAREMONT, Calif., Nov. 24 Keck Graduate Institute,s (KGI) Biotechnology ... educational event on Monday, Dec. 8, 2008. , ... (TCA), a network of individual investors who fund early-stage, technology ... of the public interested in becoming angel investors. The ...
... Omrix,s Biopharmaceutical Expertise Complements ETHICON,s Industry-Leading Surgery Portfolio ... N.J. and NEW YORK, Nov. 24 Johnson & ... Inc. (Nasdaq: OMRI ), a fully integrated ... products, today announced a definitive agreement whereby Omrix will ...
Cached Biology Technology:KGI Entrepreneur Program Hosts Angel Investing Educational Meeting 2Johnson & Johnson Announces Definitive Agreement to Acquire Omrix 2Johnson & Johnson Announces Definitive Agreement to Acquire Omrix 3Johnson & Johnson Announces Definitive Agreement to Acquire Omrix 4Johnson & Johnson Announces Definitive Agreement to Acquire Omrix 5
(Date:12/17/2014)... Research and Markets ( http://www.researchandmarkets.com/research/9zq33j/global_chemical ) has ... Market 2015-2019" report to their offering. ... trend upcoming in this market is the increasing demand ... in recording of patient data for quick and correct ...
(Date:12/11/2014)... 09, 2014 Research and Markets , ... ) has announced the addition of the "Biometrics ... One major trend emerging in this ... biometric systems utilize more than one characteristic of an ...
(Date:12/10/2014)... a leader in performance biometric data sensor technology, today ... licensees for highly accurate, clinically validated biometric technology. This ... fitness and health sectors, but first responders/military and gaming ... as useful as the biometric data it delivers. As ...
Breaking Biology News(10 mins):Global Chemical Sensor Market 2015-2019: Key Vendors are Abbott Laboratories, Bayer, Hoffmann La-Roche, Johnson & Johnson, NGK Spark Plugs and Robert Bosch 2Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2
... RALEIGH, NC Methyl bromide (MeBr) is a highly ... control a wide variety of pests. Under the Montreal ... of the chemicals that contributed to the depletion of ... reduction in the amount of MeBr produced and imported ...
... Progress , Burnham Institute for Medical ... and license agreement with Johnson & Johnson ... this multi-year agreement, Burnham will provide J&JPRD ... to investigate certain drug targets for inflammatory ...
... Mass., Feb. 3, 2009 -- Despite the striking aromatic ... of the nose,s neural circuitry suggests a haphazard patchwork ... likely as not to be neighbors. Inexplicably, this ... even species, with cells that process the same scent ...
Cached Biology News:Methyl bromide alternatives indicated for North Carolina tomato production 2The Burnham Buzz, February 2009 2Neural mapping paints a haphazard picture of odor receptors 2
ABIN-2 Polyclonal Ab 100 ug rabbit polyclonal antibody. Detects ABIN-2 in human/mouse. Tested in WB....
... 100 slides. Immunocytochemistry.Sample types: suitable for ... labeling.Recommended cell number: 10 6-107 ... at 2-8 C (except DAB: -15 ... & Cellular Assays, Assays . Specific ...
CLIM-2 (T-16)...
... and affinity purification of small components ... monodisperse magnetic particles (2.8 m in ... surface activation is not required. Allows ... orientation for affinity purification of proteins. ...
Biology Products: